Juan Journey
with Zerpidio
Juan’s Journey: A Story of Hope
Juan never imagined that his persistent cough and fatigue would turn into something so serious. At just 58 years old, he was diagnosed with squamous non-small cell lung cancer (Sq NSCLC). The news hit hard—like a storm he wasn’t prepared for. Everything in his life changed in an instant.
Struggles and Setbacks
The initial treatment plan didn’t bring the improvements his doctors had hoped for. Juan’s body felt weaker, and his spirit began to fade. He struggled with uncertainty, and some days felt darker than others. But in his heart, he still held on to one thing—hope.
A New Hope: Serplulimab
Then came a turning point. His oncologist introduced a new option: Serplulimab, an immunotherapy that helps the immune system recognize and attack cancer cells. Though unfamiliar with it at first, Juan decided to give it a try. He knew it might be his best shot.
Step by Step, Getting Stronger
The road was not easy. There were side effects and emotional lows, but Juan noticed small changes—breathing became easier, his energy returned, and most importantly, his scans showed progress. The cancer was shrinking, and his body was responding.
Victory Against the Odds
Months passed, and then came the words he had prayed for: “Your cancer is in remission.” It was a moment Juan would never forget. The fight had been long, but with Serplulimab, medical care, and unshakable determination, Juan had done the impossible—he had overcome cancer.
A Life Renewed
Today, Juan cherishes the simple things—mornings with his grandchildren, walks in the park, laughter with friends. He often shares his story with others battling cancer, offering the same hope that once saved him.
“I’m not just surviving—I’m living,” Juan says, his eyes full of life and gratitude.
Badan POM-Approved Indications
Serplulimab is approved by BPOM Indonesia for Extensive-Stage Small Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer
NMPA-Approved Indications
Serplulimab is approved by NMPA China for MSI-H solid tumors, Extensive-Stage Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cancer, and esophageal squamous cell carcinoma
EMA-Approved Indications
Serplulimab is approved by the European Medicines Agency (EMA) for Extensive-Stage Small Cell Lung Cancer
FDA-Approved as orphan drug
Serplulimab approved by United States Food and Drug Administration (US FDA) as an orphan drug for Extensive-Stage Small Cell Lung Cancer
Thai FDA-Approved Indications
Serplulimab is approved by Thai FDA for Extensive-Stage Small Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer
NPRA-Approved Indications
Serplulimab is approved by National Pharmaceutical Regulatory Agency (NPRA) for Extensive-Stage Small Cell Lung Cancer
HSA SG-Approved Indications
Serplulimab is approved by Health Science Authority (HSA) for Extensive-Stage Small Cell Lung Cancer
MHRA UK-Approved Indications
Serplulimab is approved by Medicines and Healthcare products Regulatory Agency (MHRA) UK for Extensive-Stage Small Cell Lung Cancer
CDSCO India-Approved Indications
Serplulimab is approved by Central Drugs Standard Control Organization (CDSCO) India for Extensive-Stage Small Cell Lung Cancer
MOH Cambodia-Approved Indications
Serplulimab is approved by Ministry of Health (MoH) Cambodia for Extensive-Stage Small Cell Lung Cancer
Tell your doctor if:
You have a history of :
Allergic reaction to other monoclonal antibody therapies
Kidney damage
Autoimmune disease
Organ transplant
Lung problems or breathing problems
Liver problems
You are pregnant or plan to become pregnant
You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.
Tell your doctor or nurse immediately if you have any signs or symptoms below:
Inflammation of the lungs: new or worsening cough, shortness of breath, or chest pain;
Inflammation of the liver: nausea or vomiting, feeling less hungry, pain on the right side of your stomach, yellowing of skin or whites of eyes, drowsiness, dark urine or bleeding or bruising more easily than normal;
Inflammation of the intestines: diarrhoea or more bowel movements than usual, or stools that are black, tarry or sticky with blood or mucus, severe stomach pain or tenderness;
Inflammation of glands (especially the thyroid, adrenal, pituitary and pancreas): fast heart rate, extreme tiredness, weight gain or weight loss, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away or unusual headaches, abdominal pain, nausea and vomiting;
Type 1 diabetes: high blood sugar, feeling more hungry or thirsty than usual, passing urine more often than usual, fast and deep breathing, confusion, or a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat;
Inflammation of the kidneys: decrease in the amount of urine you pass;
Inflammation of the skin: rash, itching, skin blistering, or ulcers in the mouth or on another moist surfaces;
Inflammation of the heart muscle: chest pain, shortness of breath, or irregular heartbeat;
Inflammation of the eyes;
Inflammation or problem of the muscles: muscle pain, or weakness, or rapid fatigue of the muscles;
Infusion-related reactions: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever ;
Inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): seizure, neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness;
Inflammation of the nerves: pain, weakness, and paralysis in the extremities (Guillain-Barre syndrome)
Low number of platelets: bleeding (nose or gum bleeding) and/or bruising.
Zerpidio should not be used in children and adolescents under 18 years of age. The safety and efficacy of Zerpidio in children and adolescents below 18 years of age have not been established. No data are available.
The use of Zerpidio during pregnancy and breast-feeding is not recommended. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
The most frequent adverse events of Zerpidio in combination with carboplatin and etoposide for treatment in adults with extensive-stage small cell lung cancer include neutropenia, leukopenia, and anemia.
The most frequent adverse events of Zerpidio in combination with carboplatin and nanoparticle albumin bound paclitaxel for treatment in adult patients with advanced squamous non-small cell lung cancer (metastasis/locally advanced) include anaemia, neutrophil count decreased, and white blood cell count decreased.
These are not all the possible side effects of Zerpidio. Talk to your health care provider for medical advice about side effects.
Please read the accompanying Medication Guide for Zerpidio and discuss it with your doctor. The physician Prescribing Information also is available.
Reference: Zerpidio [package insert and patient information leaflet]. Jakarta, Indonesia; 2025.
Important Safety Information
Badan POM-Approved Indications
Serplulimab is approved by BPOM Indonesia for Extensive-Stage Small Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer
NMPA-Approved Indications
Serplulimab is approved by NMPA China for MSI-H solid tumors, Extensive-Stage Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cancer, and esophageal squamous cell carcinoma
EMA-Approved Indications
Serplulimab is approved by the European Medicines Agency (EMA) for Extensive-Stage Small Cell Lung Cancer
FDA-Approved as orphan drug
Serplulimab approved by United States Food and Drug Administration (US FDA) as an orphan drug for Extensive-Stage Small Cell Lung Cancer
Thai FDA-Approved Indications
Serplulimab is approved by Thai FDA for Extensive-Stage Small Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer
NPRA-Approved Indications
Serplulimab is approved by National Pharmaceutical Regulatory Agency (NPRA) for Extensive-Stage Small Cell Lung Cancer
HSA SG-Approved Indications
Serplulimab is approved by Health Science Authority (HSA) for Extensive-Stage Small Cell Lung Cancer
MHRA UK-Approved Indications
Serplulimab is approved by Medicines and Healthcare products Regulatory Agency (MHRA) UK for Extensive-Stage Small Cell Lung Cancer
CDSCO India-Approved Indications
Serplulimab is approved by Central Drugs Standard Control Organization (CDSCO) India for Extensive-Stage Small Cell Lung Cancer
MOH Cambodia-Approved Indications
Serplulimab is approved by Ministry of Health (MoH) Cambodia for Extensive-Stage Small Cell Lung Cancer
Tell your doctor if:
You have a history of :
Allergic reaction to other monoclonal antibody therapies
Kidney damage
Autoimmune disease
Organ transplant
Lung problems or breathing problems
Liver problems
You are pregnant or plan to become pregnant
You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.
Tell your doctor or nurse immediately if you have any signs or symptoms below:
Inflammation of the lungs: new or worsening cough, shortness of breath, or chest pain;
Inflammation of the liver: nausea or vomiting, feeling less hungry, pain on the right side of your stomach, yellowing of skin or whites of eyes, drowsiness, dark urine or bleeding or bruising more easily than normal;
Inflammation of the intestines: diarrhoea or more bowel movements than usual, or stools that are black, tarry or sticky with blood or mucus, severe stomach pain or tenderness;
Inflammation of glands (especially the thyroid, adrenal, pituitary and pancreas): fast heart rate, extreme tiredness, weight gain or weight loss, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away or unusual headaches, abdominal pain, nausea and vomiting;
Type 1 diabetes: high blood sugar, feeling more hungry or thirsty than usual, passing urine more often than usual, fast and deep breathing, confusion, or a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat;
Inflammation of the kidneys: decrease in the amount of urine you pass;
Inflammation of the skin: rash, itching, skin blistering, or ulcers in the mouth or on another moist surfaces;
Inflammation of the heart muscle: chest pain, shortness of breath, or irregular heartbeat;
Inflammation of the eyes;
Inflammation or problem of the muscles: muscle pain, or weakness, or rapid fatigue of the muscles;
Infusion-related reactions: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever ;
Inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): seizure, neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness;
Inflammation of the nerves: pain, weakness, and paralysis in the extremities (Guillain-Barre syndrome)
Low number of platelets: bleeding (nose or gum bleeding) and/or bruising.
Zerpidio should not be used in children and adolescents under 18 years of age. The safety and efficacy of Zerpidio in children and adolescents below 18 years of age have not been established. No data are available.
The use of Zerpidio during pregnancy and breast-feeding is not recommended. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
The most frequent adverse events of Zerpidio in combination with carboplatin and etoposide for treatment in adults with extensive-stage small cell lung cancer include neutropenia, leukopenia, and anemia.
The most frequent adverse events of Zerpidio in combination with carboplatin and nanoparticle albumin bound paclitaxel for treatment in adult patients with advanced squamous non-small cell lung cancer (metastasis/locally advanced) include anaemia, neutrophil count decreased, and white blood cell count decreased.
These are not all the possible side effects of Zerpidio. Talk to your health care provider for medical advice about side effects.
Please read the accompanying Medication Guide for Zerpidio and discuss it with your doctor. The physician Prescribing Information also is available.
Reference: Zerpidio [package insert and patient information leaflet]. Jakarta, Indonesia; 2025.
Important Safety Information